LEVOFLOXACIN Film-coated tablet (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Levofloxacin 250 mg Film-coated Tablets.
Qualitative and quantitative composition
Each film coated tablet contains 250 mg of levofloxacin as active substance corresponding to 256.23 mg of levofloxacin hemihydrate. For the full list of excipients, see section 6.1.
Pharmaceutical form
Film-coated tablet. For 250 mg tablets: Pink coloured, capsule shaped, biconvex, film coated tablet with break line on both sides. Debossed L and F either side of the break line on one face. The tablet ...
Therapeutic indications
Levofloxacin Tablets is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1): Acute bacterial sinusitis. Acute exacerbations of chronic bronchitis. Community-acquired ...
Posology and method of administration
Levofloxacin Tablets are administered once or twice daily. The dosage depends on the type and severity of the infection and the sensitivity of the presumed causative pathogen. Treatment time The duration ...
Contraindications
Levofloxacin Tablets must not be used: In patients hypersensitive to levofloxacin or other quinolones or to any of the excipients listed in section 6.1. In patients with epilepsy. In patients with history ...
Special warnings and precautions for use
Epidemiologic studies report an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population. Therefore, fluoroquinolones should only be used ...
Interaction with other medicinal products and other forms of interaction
Effect of other medicinal products on levofloxacin Iron salts, zinc salts, magnesium- or aluminium-containing antacids, didanosine Levofloxacin absorption is significantly reduced when iron salts, or magnesium- ...
Fertility, pregnancy and lactation
Pregnancy There are limited amount of data with respect to the use of levofloxacin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity ...
Effects on ability to drive and use machines
Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patients ability to concentrate and react, and therefore may constitute a risk in situations where these ...
Undesirable effects
The information given below is based on data from clinical studies in more than 8300 patients and on extensive post marketing experience. Frequencies are defined using the following convention: very common ...
Overdose
According to toxicity studies in animals or clinical pharmacology studies performed with supra-therapeutic doses, the most important signs to be expected following acute overdosage of levofloxacin are ...
Pharmacodynamic properties
Pharmacotherapeutic group: Antiifectives for systemic use – Antibacterials for systemic use – Quinolone antibasterials – Fluoroquinolones ATC code: J01MA12 Levofloxacin is a synthetic antibacterial agent ...
Pharmacokinetic properties
Absorption Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1-2 h. The absolute bioavailability is 99-100%. Food has little ...
Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development. ...
List of excipients
Tablet core: Povidone Crospovidone (Type-B) Cellulose microcrystalline Magnesium stearate Silica colloidal anhydrous Tablet coating: Hypromellose E5 Talc Titanium dioxide (E171) Macrogol 400 Yellow ferric ...
Incompatibilities
Not applicable.
Shelf life
Shelf life: 3 years.
Special precautions for storage
This medicinal product does not require any special storage conditions.
Nature and contents of container
Tablets are packed in PVC/aluminium blisters. For 250 mg, the tablets are provided in pack sizes of 1, 2, 3, 5, 7, 10, 30, 50 and 200 tablets. Not all pack sizes may be marketed.
Special precautions for disposal and other handling
No special requirements. Any unused product or waste material should be disposed of in accordance with local requirements.
Marketing authorization holder
Accord Healthcare Limited, Sage House, 319, Pinner Road, North Harrow, Middlesex, HA1 4 HF, United Kingdom
Marketing authorization number(s)
PL 20075/0297
Date of first authorization / renewal of the authorization
02/06/2011
Date of revision of the text
25/01/2019
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
